FibroGen Inc.

FibroGen develops biopharma solutions for unmet diseases, including Roxadustat (renal anemia, MDS) in Phase III and FG‑3165/FG‑3175 anti‑GAL‑9 antibodies for solid tumors. Partnerships with Astellas and AstraZeneca support global growth.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 225
HQ: San Francisco

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
FGEN	FibroGen Inc. Cap: 0.0B	EQUITY	NMS	USD	US31572Q8087	Active	📈